Understanding downstream service profitability generated by dermatology faculty in an academic medical center: a key driver to promotion of access-to-care.

"Declarations Conflict of interestRoss L. Pearlman has accepted grant funding from the American Academy of Dermatology (AAD) and served on an advisory board for Castle Biosciences. Robert T. Brodell is a principal investigator for a clinical trial (Novartis) and for the Corevitas psoriasis biologic registry. He has stock in Veradermics, Inc. Vinayak K. Nahar, Taylor S. Ferris, William T. Sisson, and William H. Black have no conflicts of interest. Conflict of interest Ross L. Pearlman has accepted grant funding from the American Academy of Dermatology (AAD) and served on an advisory board for Castle Biosciences. Robert T. Brodell is a principal investigator for a clinical trial (Novartis) and for the Corevitas psoriasis biologic registry. He has stock in Veradermics, Inc. Vinayak K. Nahar, Taylor S. Ferris, William T. Sisson, and William H. Black have no conflicts of interest."

"Declarations: Conflict of interestRoss L. Pearlman has accepted grant funding from the American Academy of Dermatology (AAD) and served on an advisory board for Castle Biosciences. Robert T. Brodell is a principal investigator for a clinical trial (Novartis) and for the Corevitas psoriasis biologic registry. He has stock in Veradermics, Inc. Vinayak K. Nahar, Taylor S. Ferris, William T. Sisson, and William H. Black have no conflicts of interest. Conflict of interest: Ross L. Pearlman has accepted grant funding from the American Academy of Dermatology (AAD) and served on an advisory board for Castle Biosciences. Robert T. Brodell is a principal investigator for a clinical trial (Novartis) and for the Corevitas psoriasis biologic registry. He has stock in Veradermics, Inc. Vinayak K. Nahar, Taylor S. Ferris, William T. Sisson, and William H. Black have no conflicts of interest."